Overview and legislative background of Hong Kong’s pharmaceutical licensing regime

Chapter 1: Overview of Hong Kong’s Pharmaceutical Licensing System and Legislative Background

Hello, everyone! I am Drew Tang, Business Manager at Rengangyongsheng (Hong Kong) Limited, focusing on compliance consultancy and application services for various Hong Kong licences for clients in Hong Kong and overseas. In the course of my career, RGYS may assist with document preparation and project coordination within the written scope of services; personnel qualifications, statutory roles and professional judgements are to be verified and assumed by the respective responsible parties, while approval is determined independently by the competent authority. I am well aware that the complexity and specialist nature of Hong Kong's pharmaceutical licensing system inspire both curiosity and concern. Through this guide, I therefore hope to share systematically my project materials, the current supporting basis and my understanding of the regulations, helping you gain a clear and accurate grasp of the key points of pharmaceutical licence applications in Hong Kong. In this chapter, we will begin with a broad overview of the overall framework of Hong Kong's pharmaceutical licensing system and its extensive legislative background.

1.1 Overview of the Hong Kong pharmaceutical market and its international standing

As an international financial and trading centre, Hong Kong also has a highly developed pharmaceutical market that is closely aligned with international standards. Its unique geographical location, free-port policy and robust legal system have made Hong Kong an important gateway for leading global pharmaceutical companies entering Asian markets, particularly Mainland China. Although Hong Kong’s pharmaceutical market is not large, its stringent regulatory standards and high level of professionalism enjoy an excellent international reputation. The approval standards and procedures of the Drug Office, Department of Health, draw extensively on best practices of leading international authorities such as the US FDA and the European EMA, and it works closely with international organisations including PIC/S (the Pharmaceutical Inspection Co-operation Scheme). Medicines approved for marketing in Hong Kong are therefore often regarded as a ‘gold standard’ for quality and safety, helping pave the way for their registration and sale in other markets.

In addition, Hong Kong has world-class healthcare infrastructure, a professional healthcare workforce and a well-established pharmaceutical supply chain. Every stage, from research and development and manufacturing to wholesale and retail, is closely regulated to ensure the quality and safety of medicines. Companies wishing to conduct pharmaceutical business in Hong Kong—whether establishing an R&D centre or manufacturing base, or carrying out import and export trade—can find development opportunities in this mature, well-regulated market. Of course, opportunities come with challenges, and a thorough understanding of and strict compliance with the local drug licensing system is the first step to success.

1.2 Historical development and core objectives of the pharmaceutical licensing system

Hong Kong’s medicine regulatory system did not emerge all at once; it has evolved and been refined over more than a century. Its history can be traced to the late 19th century, when legislation focused mainly on controlling “poisons”. As modern pharmacy developed and new medicines emerged, the relevant laws and regulations evolved accordingly. A key milestone was the enactment and subsequent amendment of the current Pharmacy and Poisons Ordinance (Cap. 138) and its subsidiary regulations, which form the legal foundation of modern medicine regulation in Hong Kong. This development reflects the Hong Kong Government’s growing emphasis on public safety in the use of medicines. The regulatory approach has shifted from reactive control to proactive, systematic and end-to-end risk management.

In my view, the core objectives of Hong Kong’s pharmaceutical licensing system have always centred on the following: first, protecting public health, which is the starting point and ultimate aim of all regulatory measures, ensuring that the public has access to medicines that are safe, effective and of reliable quality. Second, ensuring the safety and efficacy of medicines, using stringent registration and approval, Good Manufacturing Practice (GMP) and post-marketing monitoring to keep substandard or potentially risky medicines off the market. Finally, regulating the distribution of medicines, by setting clear requirements at every stage, from manufacturers and wholesalers to retail outlets (pharmacies and dispensaries), covering operators’ qualifications, storage and transport conditions, and sales practices. This helps prevent counterfeit and substandard medicines from entering the market and safeguards the integrity of the legitimate supply chain.

“This Ordinance provides for the possession, sale, supply and distribution of pharmaceuticals, poisons and any other substances (whether or not intended for use as medicines); the registration of pharmaceutical products; and matters incidental or related thereto.”

1.3 Legislative background and core principles of the Pharmacy and Poisons Ordinance

A discussion of Hong Kong’s medicines licensing system must begin with its fundamental legislation—the Pharmacy and Poisons Ordinance (Cap. 138). The Ordinance was enacted in response to lessons from numerous serious medicines-related incidents in the past, as well as a recognition of the complexity of risks posed by modern medicines. It establishes the Pharmacy and Poisons Board (PPB) as the central decision-making body and the Drug Office, Department of Health, as the implementing body. Its core principles are ‘risk-based regulation’ and ‘regulation throughout the lifecycle’.

‘Risk-based’ means that the intensity of regulation is commensurate with the potential risks of medicines. For example, the Ordinance classifies medicines according to their ingredients and uses (such as Part I poisons, Part II poisons, antibiotics and dangerous drugs) and sets different conditions for their sale—some must be sold in a pharmacy under the supervision of a registered pharmacist, while others may be sold by a licensed medicines retailer. This classification system carefully balances access to medicines with safety. ‘Regulation throughout the lifecycle’ means that the Ordinance’s scope covers medicines from ‘cradle to grave’: from research and clinical trials through registration, manufacture, import, wholesale and retail, to final disposal, with every stage covered and no gaps.

The table below clearly sets out the main Hong Kong legislation relating to medicines and its regulatory scope, helping readers establish an overview of the legal framework.